MedTrace Logo

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 799

Last updated 2012-02-22

No results posted yet for this study

Summary

The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD

Conditions

Interventions

DRUG

arformoterol

Arformoterol inhalation solution, 50 mcg QD

DRUG

Salmeterol

Salmeterol MDI, 42 mcg BID

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2004-12-31
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064415 on ClinicalTrials.gov